Name

Kazuyuki Inoue

Current Status

Associate Professor

Department of Clinical Pharmacology & Genetics,

School of Pharmaceutical Science, University of Shizuoka.

Date of Birth

November 1972

Education

2004 Ph.D. in Medicine, Akita University

1997 M.S. in Pharmaceutical Science, Tohoku University

1995 B.S. in Pharmaceutical Science, Tohoku University

Experience

2016.10-present	Associate Professor
	Department of Clinical Pharmacology & Genetics,
	School of Pharmaceutical Science, University of Shizuoka.
2008.4-2016.9	Assistant Professor
	Department of Clinical Pharmacology & Genetics,
	School of Pharmaceutical Science, University of Shizuoka.
2002.4-2008.3	Chief Pharmacist

	Department of Pharmaceutical Science, Akita University Hospital
2000.4-2002.3	Pharmacist Department of Pharmaceutical Science, Tohoku University Hospital
1997.4-2000.3	Pharmacist Department of Pharmaceutical Science, Akita University Hospital

Award

2003	The Pharmaceutical Society of Japan Tohoku Branch Award for Young Scientists

Recent Publications (From 2008)

1. Yokoi M, Tsuji D, Suzuki K, Kawasaki Y, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. *Support Care Cancer*. **26(5)**, 1505-1513 (2018)
2. Hirai K, Shirai T, Suzuki M, Akamatsu T, Suzuki T, Hayashi I, Yamamoto A, Akita T, Morita S, Asada K, Tsuji D, **Inoue K**, Itoh K. A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype. *Clin Exp Allergy*. **47(11)**, 1374-1382 (2017)
3. Otake A, Tsuji D, Taku K, Kawasaki Y, Yokoi M, Nakamori H, Osada M, Matsumoto

M, **Inoue K**, Hirai K, Itoh K. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. *Eur J Clin Pharmacol*. **73(8)**, 1033-1039 (2017).

4. Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, **Inoue K**, Hama T, Takeda K, Nishio M, Itoh K. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. *Pharmacogenomics J*. **17(5)**, 435-440 (2017)
5. Tsuji D, Ikeda M, Yamamoto K, Nakamori H, Kim Y, Kawasaki Y, Otaki A, Yokoi M, **Inoue K**, Hirai K, Nakamichi H, Tokou U, Shiokawa M, Itoh K. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study. *Medicine*. **95(44)**, e5151 (2016)
6. Hirai K, Ishii H, Shimoshikiryo T, Shimomura T, Tsuji D, **Inoue K**, Kadoiri T, Itoh K. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin. *Ther Drug Monit.* **38(6)**, 706-710 (2016)
7. Hirai K, Shimomura T, Moriwaki H, Ishii H, Shimoshikiryo T, Tsuji D, **Inoue K**, Kadoiri T, Itoh K. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. *Eur J Clin Pharmacol*. **72(10)**, 1177-1183 (2016)
8. **Inoue K**, Murofushi T, Nagaoka K, Ando N, Hakamata Y, Suzuki A, Umemura A, Yoshida Y, Hirai K, Tsuji D, Itoh K. Influence of genetic polymorphisms and concomitant anxiolytic doses on antidepressant maintenance doses in Japanese patients with depression. *Biol Pharm Bull.* **39(9)**, 1508-13 (2016)

9. **Inoue K**, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K. Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. *Eur J Clin Pharmacol.* **72(5)**, 555-562 (2016)
10. **Inoue K**, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. *Seizure*. **33**, 76-80 (2015)
11. Tazoe Y, Hayashi H, Tsuboi S, Shioura T, Matsuyama T, Yamada H, Hirai K, Tsuji D, **Inoue K**, Sugiyama T, Itoh K. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. *Drug Metab Pharmacokinet.* **30(3)**, 227-30 (2015)
12. Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, **Inoue K**, Itoh K. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. *Thromb Res.* **135(5)**, 861-6 (2015)
13. Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y, Hatori M, Makuta R, Hayashi H, **Inoue K**, Nakamichi H, Shiokawa M, Itoh K. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. *Drug Metab Pharmacokinet.* **30(2)**, 149-53 (2015)
14. **Inoue K**, Suzuki E, Takahashi T, Yamamoto Y, Yazawa R, Takahashi Y, Imai K, Miyakawa K, Inoue Y, Tsuji D, Hayashi H, Itoh K. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia

development during valproic acid-based therapy. *Epilepsy Res*. **108(6)**, 1046-51 (2014)

15. **Inoue K**, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C<T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. *Ther Drug Monit.* **36(3)**, 406-9 (2014)
16. Saito M, Kondo M, Ohshima M, Deguchi K, Hayashi H, **Inoue K**, Tsuji D, Masuko T, Itoh K. Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization. *Cancer Sci*. **105(4)**, 396-401 (2014)
17. Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, **Inoue K**, Itoh K, Kagawa Y, Inoue Y. Risk factors for hyperammonemia in pediatric patients with epilepsy. *Epilepsia*. **54(6)**, 983-9 (2013)
18. Tsuji D, Kamezato M, Daimon T, Taku K, Hatori M, Ikeda M, Hayashi H, **Inoue K**, Eto T, Itoh K. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. *Chemotherapy.* **59(6)**,407-13 (2013)
19. Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T, Ohshima M, Matsuyama T, Kosuge K, Yamada H, Tsuji D, **Inoue K**, Itoh K. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. *Drug Metab Pharmacokinet*. **28(2)**, 164-8 (2013)
20. Tsuji D, Kim YI, Nakamichi H, Daimon T, Suwa K, Iwabe Y, Hayashi H, **Inoue K**, Yoshida M, Itoh K. Association of ABCB1 polymorphisms with the antiemetic

efficacy of granisetron plus dexamethasone in breast cancer patients. *Drug Metab Pharmacokinet*. **28(4)**, 299-304 (2013)

21. **Inoue K**, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M, Kimura M, Minami S, Utsuki H, Yamazaki T, Suzuki T, Tsuji D, Hayashi H, Itoh K. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. *Tohoku J Exp Med*. **229(2)**, 107-14 (2013)
22. Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, **Inoue K**, Itoh K, Kagawa Y, Inoue Y. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. *Epilepsy Res*. **101(3)**, 202-9 (2012)
23. **Inoue K**, Ando N, Suzuki E, Hayashi H, Tsuji D, Itoh K. Genotype distributions and allele frequencies of possible major depressive disorder-associated single nucleotide polymorphisms, cyclic adenosine monophosphate response element binding protein 1 rs4675690 and Piccolo rs2522833, in a Japanese population. *Biol Pharm Bull.* **35(2)**, 265-8 (2012)
24. Hayashi H, Tazoe Y, Horino M, Fujimaki-Katoh C, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, Tsuji D, **Inoue K**, Itoh K. An artifact derived from a pseudogene led to the discovery of microRNA binding site polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene. *Drug Metab Pharmacokinet.* **27(2)**, 263-7 (2012)
25. Ohshima M, **Inoue K**, Hayashi H, Tsuji D, Mizugaki M, Itoh K. Generation of AcGFP fusion with single-chain Fv selected from a phage display library constructed from mice hyperimmunized against 5-methyl 2'-deoxycytidine. *Protein Eng Des Sel*. **23(11)**, 881-8 (2010)

26. Hayashi H, Horino M, Morishita M, Tazoe Y, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, Tsuji D, **Inoue K**, Itoh K. Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population. *Drug Metab Pharmacokinet.* **25(5)**, 516-8 (2010)
27. Ohshima M, Tadakuma T, Hayashi H, **Inoue K**, Itoh K. Generation of a recombinant single-chain variable fragment (scFv) targeting 5-methyl-2'-deoxycytidine. *J Biochem*. **147(1)**, 135-41 (2010)
28. Miura M, **Inoue K**, Kagaya H, Saito M, Habuchi T, Satoh S. Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. *Xenobiotica*. **39(12)**, 939-45 (2009)
29. Yoshizawa M, Hayashi H, Tashiro Y, Sakawa S, Moriwaki H, Akimoto T, Doi O, Kimura M, Kawarasaki Y, **Inoue K**, Itoh K. Effect of VKORC1 -1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. *Thromb Res*. **124(2)**, 161-6 (2009)
30. Satoh S, Saito M, Inoue T, Kagaya H, Miura M, **Inoue K**, Komatsuda A, Tsuchiya N, Suzuki T, Habuchi T. CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. *Eur J Clin Pharmacol*. **65(5)**, 473-81 (2009)
31. Fujiyama N, Miura M, Satoh S, **Inoue K**, Kagaya H, Saito M, Habuchi T, Suzuki T. Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. *Xenobiotica*. **39(5)**, 407-14 (2009)

32. Fujimaki C, Hayashi H, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, **Inoue K**, Itoh K. Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis. *Biomarkers*. **14(1)**, 49-54 (2009)
33. Itoh K, Ohshima M, Sonobe M, Saito M, Yoshida A, Hayashi H, **Inoue K**, Masuko T. Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein. *Cancer Sci*. **100(1)**, 126-31 (2009)
34. Miura M, Satoh S, **Inoue K**, Saito M, Habuchi T, Suzuki T. Telmisartan pharmacokinetics in Japanese renal transplant recipients. *Clin Chim Acta*. **399(1-2)**, 83-7 (2009)
35. Miura M, Satoh S, **Inoue K**, Kagaya H, Saito M, Inoue T, Habuchi T, Suzuki T. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. *Steroids*. **73(11)**, 1052-9 (2008)
36. Miura M, Kagaya H, Satoh S, **Inoue K**, Saito M, Habuchi T, Suzuki T. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. *Ther Drug Monit*. **30(5)**, 559-64 (2008)
37. Saito M, Satoh S, Kagaya H, Tsuruta H, Obara T, Kumazawa T, Inoue T, **Inoue K**, Miura M, Yuasa T, Komatsuda A, Tsuchiya N, Habuchi T. Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus. *Clin Exp Nephrol*. **12(4)**, 312-5 (2008)
38. Satoh S, Kagaya H, Saito M, Inoue T, Miura M, **Inoue K**, Numakura K, Tsuchiya N, Tada H, Suzuki T, Habuchi T. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in

Japanese renal transplant recipients. *Br J Clin Pharmacol*. **66(2)**, 207-14 (2008)

39. Kagaya H, Miura M, Satoh S, **Inoue K**, Saito M, Inoue T, Habuchi T, Suzuki T. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. *J Clin Pharm Ther*. **33(2)**, 193-201 (2008)
40. Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, **Inoue K**, Suzuki T, Itoh K, Ozaki N. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. *Hum Psychopharmacol*. **23(2)**, 121-8 (2008)
41. Miura M, Satoh S, **Inoue K**, Kagaya H, Saito M, Suzuki T, Habuchi T. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. *Ther Drug Monit*. **30(1)**, 46-51 (2008)